Sezai Sahmay

Publications (10)8.67 Total impact

• Article: Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients.

  Sezai Sahmay, Onur Guralp, Begum Aydogan, Ismail Cepni, Engin Oral, Tulay Irez
  [show abstract] [hide abstract]
  ABSTRACT: Abstract Objective: The purpose of this study is to investigate the role of serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH) and antral follicle count (AFC) for the prediction of clinical pregnancy rates (CPR) in women with polycystic ovary syndrome (PCOS) undergoing IVF treatment. Design: Prospective cohort study. Setting: University hospital. Patients: One hundred and fifty consecutive women with PCOS. Interventions: All women underwent controlled ovarian stimulation with long agonist protocol followed by IVF procedure. Outcomes of pregnant and non-pregnant groups were compared. Main outcome measure: CPR; AMH, FSH and AFC means and percentiles. Results: Fifty-one (34%) clinical pregnancies were observed in 150 women. Mean AMH was 6.7 ± 2.8 and 7.1 ± 4.3 ng/mL in pregnant and non-pregnant women, respectively (p = 0.594). The CPR were 27.8%, 35.0% and 37.8% in <25%, 25%-75% and >75% AMH percentiles, respectively (p = 0.656). There were also no significant difference in mean FSH and AFC between pregnant and non-pregnant women (p = 0.484 and p = 0.165, respectively). Conclusion: AMH, FSH and AFC are not predictive for CPR in women with PCOS undergoing IVF treatment. Mean AMH values were not significantly different between pregnant and non-pregnant women. Although CRP increased in parallel with the raise in AMH percentiles, this remained insignificant.
  Gynecological Endocrinology 03/2013; · 1.58 Impact Factor
• Article: The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels.

  Ali Benian, Onur Guralp, Duygu Derya Uzun, Alper Okyar, Sezai Sahmay
  [show abstract] [hide abstract]
  ABSTRACT: Objective: To evaluate the possible effect of methotrexate (MTX) on rat ovaries by measuring serum antimullerian hormone (AMH), the novel marker of the ovarian reserve. Methods: Pretreatment serum AMH levels were measured in 15 Wistar albino rats. MTX was given in 1 mg/kg dose in days 1, 3, 5, and 7. Serum AMH levels were measured twenty-four hours after each MTX administration. Pre- and post-treatment serum AMH levels were compared. Results: Pretreatment median serum AMH was 102.4 ng/mL (25%: 41.9; 75%: 179.8). The median serum AMH levels were 70.6 ng/mL (25%: 54.08; 75%: 125.5); 136.1 ng/mL (25%: 57.3; 75%: 223.09); 121.2 ng/mL (25%: 52.5; 75%: 151.5); and 104.7 ng/mL (25%: 65.8; 75%: 265.5) after the first, second, third, and fourth methotrexate administrations, respectively. The ratio of the final (eighth day) median serum AMH level to the pretreatment median AMH level was 1.27 (25%: 0.84 and 75%: 2.57). Wilcoxon related samples test showed that final AMH was significantly higher as compared to the second day AMH measurement (p = 0.041). Conclusion: MTX administration did not cause a statistically significant change between pretreatment and final serum AMH levels in rats. There was no decrease in AMH levels indicating a decrease in ovarian reserve.
  Gynecological Endocrinology 03/2013; 29(3):226-9. · 1.58 Impact Factor
• Article: Is there any correlation between amh and obesity in premenopausal women?

  Sezai Sahmay, Taner Usta, Cemal Tamer Erel, Metehan Imamoğlu, Mustafa Küçük, Nil Atakul, Hakan Seyisoğlu
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the correlation between the levels of anti-mullerian hormone and body mass index between obese and non-obese premenopausal women. Serum anti-mullerian hormone levels of women younger than 45 years admitted to our reproductive endocrinology clinic for investigation of infertility were examined in this cross-sectional study. Body mass indices were lower than 30 kg/m(2) in 222 patients and equal to or higher than 30 kg/m(2) in 37 patients. Levels of antimullerian hormone were analyzed in each group. Blood samples obtained from study subjects were assayed for levels of anti-mullerian hormone, follicle-stimulating hormone, luteinizing hormone, estradiol, prolactin and thyroid stimulating hormone. There was no significant difference in terms of mean age between the two groups. There was no statistically significant difference between these two groups in terms of FSH, LH, estradiol and prolactin levels. Anti-mullerian hormone levels were 3.46 ± 2.79 ng/ml and 3.79 ± 2.93 ng/ml in non-obese and obese participants, respectively. No statistically significant correlation was found between Anti Müllerian Hormone (AMH) levels and BMI levels in either group (P > 0.05). Body mass index does not have an effect on serum AMH levels in women of reproductive age. Obesity has no association with levels of serum follicle stimulating hormone, luteinizing hormone, estradiol, prolactin and thyroid stimulating hormone. Obesity is unlikely to affect ovarian reserve in the premenopausal age group.
  Archives of Gynecology 05/2012; 286(3):661-5. · 0.91 Impact Factor
• Article: Serum anti-müllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index

  Sezai Sahmay, Onur Guralp, Levent M. Senturk, Metehan Imamoglu, Mustafa Kucuk, Tulay Irez
  [show abstract] [hide abstract]
  ABSTRACT: PurposeTo evaluate the correlation between anti-müllerian hormone (AMH) and body mass index (BMI) in patients with and without polycystic ovarian syndrome (PCOS). MethodsSerum AMH levels of 332 women in their reproductive period and below 45years of age who were admitted to our reproductive endocrinology clinic with infertility were investigated in a cross-sectional study. Patients were divided into two groups as BMI under and equal or over 25kg/m2. Both groups were divided into two subgroups as PCOS and non-PCOS. AMH levels of patients were analyzed for each group. ResultsMean AMH values of BMI <25 and ≥25kg/m2 groups were 3.87±2.95 and 3.58±2.93ng/mL, respectively (P>0.05) in all patients. Means of AMH were not significantly different in BMI quartiles (r=−0.008401, P=0.96). Among 107 patients with PCOS, means of AMH were 6.85±2.95ng/mL in 56 patients with BMI <25kg/m2 and 6.66±3.18ng/mL in 51 patients with BMI ≥25kg/m2 (P>0.05). In the group of 225 non-PCOS patients, means of AMH were 2.27±1.12ng/mL in 104 patients with BMI <25kg/m2 and 2.28±1.49ng/mL in 121 patients with BMI ≥25kg/m2 (P>0.05). ConclusionsBody mass index does not seem to have an effect on serum AMH levels in reproductive age women both with and without PCOS. KeywordsAnti-müllerian hormone–Body mass index–Ovarian reserve–Overweight–Polycystic ovarian syndrome
  Reproductive Medicine and Biology 04/2012; 10(2):113-120.
• Article: Serum anti-Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients

  Sezai Sahmay, Meral Cetin, Pelin Ocal, Semih Kaleli, Hulya Senol, Fatih Birol, Tulay Irez
  [show abstract] [hide abstract]
  ABSTRACT: PurposeTo evaluate the clinical value of day 3 serum anti-Müllerian hormone (AMH) compared with day 3 serum follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG) day estradiol (E2) levels and antral follicle count (AFC) in the prediction of poor ovarian response in controlled ovarian hyperstimulation (COH). MethodsAMH, FSH and AFC on day 3 as well as hCG day E2 levels were determined in 164 subjects. Receiver operating curve analyses and area under curves (AUC) of the study parameters were performed. Predictive values of the levels of day 3 AMH, FSH, AFC, and hCG day E2 as clinical parameters of ovarian response to COH were studied. ResultsThirty-eight women were defined as poor responders. The day 3 AMH and hCG day E2 levels and AFC of normal responders were significantly higher than those of the poor responders. In predicting poor response, the AUC of day 3 AMH level was significantly higher than that of day 3 FSH level but was similar to the hCG day E2 level. Day 3 AMH, FSH and hCG day E2 levels and AFC were found to predict a poor response. Day 3 AMH and hCG day E2 levels were more predictive compared with day 3 FSH level and AFC. The cut-off level of AMH was ≤2 with a sensitivity of 78.9% and a specificity of 73.8%. ConclusionDay 3 AMH has the ability to predict a poor response to COH and it is more predictive than day 3 FSH and AFC. KeywordsAnti-Müllerian hormone–Follicle-stimulating hormone–Antral follicle count–In vitro fertilization–Intracytoplasmic sperm injection–Poor responders–Infertility
  Reproductive Medicine and Biology 04/2012; 10(1):9-14.
• Article: Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles.

  Sezai Sahmay, Gökhan Demirayak, Onur Guralp, Pelin Ocal, Levent M Senturk, Engin Oral, Tulay Irez
  [show abstract] [hide abstract]
  ABSTRACT: To investigate whether serum anti-müllerian hormone (AMH), follicle stimulating hormone (FSH), or antral follicle count (AFC) are predictive for clinical pregnancy in in vitro fertilization (IVF) patients. Serum AMH, inhibin B, FSH, luteinizing hormone (LH), estradiol (E2), prolactin, and thyroid stimulating hormone (TSH) levels and AFC of 189 women under 40 years of age were investigated. Pregnant and non-pregnant women were compared. Forty-seven (24.8 %) clinical pregnancies were observed in 189 women. There was no significant difference in terms of mean age, duration of infertility, body mass index, AMH, LH, FSH, E2, TSH, Inhibin B, AFC and total oocyte number between women who did and who did not become pregnant. Additionally, there was no significant difference in clinical pregnancy rates between the quartiles of AMH, FSH and AFC. (P values were 0.668, 0.071, and 0.252, respectively.) Serum AMH and FSH, and AFC cannot predict clinical pregnancy in IVF patients under 40; the pregnancy rate tends to increase as AMH increases, although this remains non-significant.
  Journal of Assisted Reproduction and Genetics 04/2012; 29(7):589-95. · 1.84 Impact Factor
• Article: Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles.

  Pelin Ocal, Sezai Sahmay, Meral Cetin, Tulay Irez, Onur Guralp, Ismail Cepni
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate predictive role of day-3 serum anti-Müllerian hormone (AMH) levels and antral follicle count (AFC) in ovarian hyperstimulation syndrome (OHSS) in patients undergoing IVF/ICSI cycles. Forty-one women with moderate/severe OHSS and 41 age matched women without OHSS were compared to evaluate the predictive value of certain risk factors for OHSS. AFC, and E(2), FSH, LH, AMH, inhibin-B levels measured on day 3 of the menstrual cycle before controlled ovarian hyperstimulation. Mean FSH was significantly lower (p < 0.0001); and mean LH, AFC and AMH were significantly higher in women with OHSS compared to women without OHSS (p = 0.049, p < 0.0001 and p < 0.0001, respectively). There was no significant difference in inhibin B (p = 0.112) and estradiol (p = 0.706) between the groups. The ROC area under curve (AUC) for AMH presented the largest AUC among the listed risk factors. AMH (AUC = 0.87) and AFC (AUC = 0.74) had moderate accuracy for predicting OHSS while Inhibin B (AUC = 0.58) and LH (AUC = 0.61) had low accuracy. The cut-off value for AMH 3.3 ng/mL provided the highest sensitivity (90%) and specificity (71%) for predicting OHSS. It's positive (PPV) and negative predictive values (NPV) were 61% and 94%, respectively. The cut-off value for AFC was 8 with 78% sensitivity, 65% specificity, 52% PPV and 86% NPV. Measurement of basal serum AMH and AFC can be used to determine the women with high risk for OHSS.
  Journal of Assisted Reproduction and Genetics 09/2011; 28(12):1197-203. · 1.84 Impact Factor
• Article: Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes.

  Tulay Irez, Pelin Ocal, Onur Guralp, Meral Cetin, Begum Aydogan, Sezai Sahmay
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the association between different basal serum levels of anti-Müllerian hormone (AMH) and oocyte-embryo quality and IVF outcomes. Two hundred and nine infertile women who underwent in vitro fertilization treatment with intracytoplasmic sperm injection (ICSI) between January 2009 and February 2011 were included in the study. Mean age, BMI, FSH, E(2), inhibin B, duration of infertility, total gonadotropin dose, antral follicle count, morphology of all oocytes, percentage of MII, early cleavage rate, the number of good quality embryos in transfer and ongoing pregnancy (>12 weeks) rates were evaluated. Six groups were formed according to the percentiles as <10% (≤0.89 ng/ml; n = 21), 10-25% (0.89-1.40 ng/ml; n = 31), 25-50% (1.40-2.89 ng/ml; n = 53), 50-75% (2.89-4.83 ng/ml; n = 28), 75-90% (4.83-8.06 ng/ml; n = 55), >90% (>8.06 ng/ml; n = 21). Central granulation, cytoplasmic granulation, oocyte postmaturity, percentage of embryos, early cleavage and percentage of transferred good quality embryos were significantly different in five groups (ANOVA test). Ongoing pregnancy rate (PR) was the lowest in <10% (9.5%), and the highest in 50-75% group (39.3%). (P = 0.040) Different AMH levels may predict the quality of oocytes, presence of postmaturity and nucleoli Z score, early cleavage and ICSI outcomes.
  Archives of Gynecology 07/2011; 284(5):1295-301. · 0.91 Impact Factor
• Article: Serum antimüllerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index

  Sezai Sahmay, Onur Guralp, Levent M.Senturk, metehan Imamoglu, Mustafa Kucuk, Tulay Irez
  Reproductive Medicine and Biology. 01/2011; 10:113- 120.
• Article: Serum antimüllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients

  Sezai Sahmay, Meral Cetin, Pelin Ocal, Semih kaleli, Hulya Senol, Fatih Birol, Tulay Irez
  Reproductive Medicine and Biology. 01/2011; 10:9-14.